These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 29687317)

  • 41. Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure.
    Cavusoglu Y; Mert U; Nadir A; Mutlu F; Morrad B; Ulus T
    J Cardiovasc Med (Hagerstown); 2015 Sep; 16(9):603-9. PubMed ID: 24922198
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [How to evaluate and treat heart failure with preserved left ventricular ejection fraction].
    Cohen Solal A; Tournoux F; Beauvais F; Tartiere JM
    Therapie; 2009; 64(2):101-9. PubMed ID: 19664403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
    Mulder P; Barbier S; Chagraoui A; Richard V; Henry JP; Lallemand F; Renet S; Lerebours G; Mahlberg-Gaudin F; Thuillez C
    Circulation; 2004 Apr; 109(13):1674-9. PubMed ID: 14981003
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiac diastolic and autonomic dysfunction are aggravated by central chemoreflex activation in heart failure with preserved ejection fraction rats.
    Toledo C; Andrade DC; Lucero C; Arce-Alvarez A; Díaz HS; Aliaga V; Schultz HD; Marcus NJ; Manríquez M; Faúndez M; Del Rio R
    J Physiol; 2017 Apr; 595(8):2479-2495. PubMed ID: 28181258
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ivabradine: Role in the Chronic Heart Failure Armamentarium.
    Psotka MA; Teerlink JR
    Circulation; 2016 May; 133(21):2066-75. PubMed ID: 27217432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does heart rate really matter to patients with heart failure?
    Miller RJ; Howlett JG
    Curr Opin Cardiol; 2017 Mar; 32(2):209-216. PubMed ID: 27984253
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction.
    Floras JS; Ponikowski P
    Eur Heart J; 2015 Aug; 36(30):1974-82b. PubMed ID: 25975657
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How Heart Rate Should Be Controlled in Patients with Atherosclerosis and Heart Failure.
    da Silva RMFL; Borges ASR; Silva NP; Resende ES; Tse G; Liu T; Roever L; Biondi-Zoccai G
    Curr Atheroscler Rep; 2018 Sep; 20(11):54. PubMed ID: 30225613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E; Lerebours G; Vilaine JP
    Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ivabradine: Current and Future Treatment of Heart Failure.
    Thorup L; Simonsen U; Grimm D; Hedegaard ER
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):89-97. PubMed ID: 28371247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris.
    Borer JS; Swedberg K; Komajda M; Ford I; Tavazzi L; Böhm M; Depre C; Wu Y; Maya J; Dominjon F
    Cardiology; 2017; 136(2):138-144. PubMed ID: 27614723
    [TBL] [Abstract][Full Text] [Related]  

  • 52. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
    Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
    Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction.
    Straw S; McGinlay M; Witte KK
    Open Heart; 2021 Mar; 8(1):. PubMed ID: 33653703
    [No Abstract]   [Full Text] [Related]  

  • 54. Is There a Role for Ivabradine in the Contemporary Management of Patients with Chronic Heart Failure in Academic and Community Heart Failure Clinics in Canada?
    Roth S; Fernando C; Azeem S; Moe GW
    Adv Ther; 2017 Jun; 34(6):1340-1348. PubMed ID: 28432646
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure.
    Oliva F; Sormani P; Contri R; Campana C; Carubelli V; Cirò A; Morandi F; Di Tano G; Mortara A; Senni M; Metra M; Ammirati E
    Int J Cardiol; 2018 Feb; 253():97-104. PubMed ID: 29249470
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Limited role for ivabradine in the treatment of chronic heart failure.
    Cullington D; Goode KM; Cleland JG; Clark AL
    Heart; 2011 Dec; 97(23):1961-6. PubMed ID: 21917660
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does Ivabradine Decrease Cardiovascular Deaths in Heart Failure Patients?
    Marciniak TA; Atar D; Serebruany V
    Am J Med; 2020 Mar; 133(3):347-351. PubMed ID: 31442391
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Update on ivabradine for heart failure.
    Borer JS; Tavazzi L
    Trends Cardiovasc Med; 2016 Jul; 26(5):444-9. PubMed ID: 26934996
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period.
    Dierckx R; Cleland JG; Parsons S; Putzu P; Pellicori P; Dicken B; Boyalla V; Clark AL
    JACC Heart Fail; 2015 Mar; 3(3):224-30. PubMed ID: 25650369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.